Home > Research > Publications & Outputs > Costs, effects and cost‐effectiveness of breast...
View graph of relations

Costs, effects and cost‐effectiveness of breast cancer control in Ghana

Research output: Contribution to journalJournal articlepeer-review

Published
  • Sten G. Zelle
  • Kofi M. Nyarko
  • William K. Bosu
  • Moses Aikins
  • Laurens M. Niëns
  • Jeremy A. Lauer
  • Cecilia R. Sepulveda
  • Jan A. C. Hontelez
  • Rob Baltussen
Close
<mark>Journal publication date</mark>08/2012
<mark>Journal</mark>Tropical Medicine and International Health
Issue number8
Volume17
Number of pages13
Pages (from-to)1031-1043
Publication StatusPublished
Early online date19/07/12
<mark>Original language</mark>English

Abstract

Breast cancer control in Ghana is characterised by low awareness, late‐stage treatment and poor survival. In settings with severely constrained health resources, there is a need to spend money wisely. To achieve this and to guide policy makers in their selection of interventions, this study systematically compares costs and effects of breast cancer control interventions in Ghana. We used a mathematical model to estimate costs and health effects of breast cancer interventions in Ghana from the healthcare perspective. Analyses were based on the WHO‐CHOICE method, with health effects expressed in disability‐adjusted life years (DALYs), costs in 2009 US dollars (US$) and cost‐effectiveness ratios (CERs) in US$ per DALY averted. Analyses were based on local demographic, epidemiological and economic data, to the extent these data were available. Biennial screening by clinical breast examination (CBE) of women aged 40–69 years, in combination with treatment of all stages, seems the most cost‐effective intervention (costing $1299 per DALY averted). The intervention is also economically attractive according to international standards on cost‐effectiveness. Mass media awareness raising (MAR) is the second best option (costing $1364 per DALY averted). Mammography screening of women of aged 40–69 years (costing $12 908 per DALY averted) cannot be considered cost‐effective. Both CBE screening and MAR seem economically attractive interventions. Given the uncertainty about the effectiveness of these interventions, only their phased introduction, carefully monitored and evaluated, is warranted. Moreover, their implementation is only meaningful if the capacity of basic cancer diagnostic, referral and treatment and possibly palliative services is simultaneously improved.